Tango Therapeutics News

Analyst Estimates: Here's What Brokers Think Of Tango Therapeutics, Inc. (NASDAQ:TNGX) After Its First-Quarter Report

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. (NASDAQ:TNGX), given that the company fell short of expectations when it released its first-quarter results last week. E

Simply Wall StMay 11 20:21

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)

TipRanksMay 10 13:30

Tango Therapeutics Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Tango Therapeutics Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow JonesMay 9 19:26

Buy Rating Affirmed for Tango Therapeutics on Promising PRMT5 Inhibitors and Strong Financials

TipRanksMay 9 18:37

Tango Therapeutics (TNGX) Gets a Buy From Barclays

TipRanksMay 9 15:26

Tango Therapeutics' Cash Position Of $344M As Of March 31, 2024; Cash Runway Into Late 2026 Expected

Tango Therapeutics' Cash Position Of $344M As Of March 31, 2024; Cash Runway Into Late 2026 Expected

BenzingaMay 8 19:36

Tango Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate, Sales $6.471M Miss $6.669M Estimate

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.31) by 12.9 percent. This is a 9.37 percent decrease over losses of $

BenzingaMay 8 19:35

Tango Therapeutics | 10-Q: Quarterly report

Futu NewsMay 8 19:23 · Announcements

Tango Therapeutics 1Q Loss/Shr 35c >TNGX

Tango Therapeutics 1Q Loss/Shr 35c >TNGX

Dow JonesMay 8 19:03

Tango Therapeutics 1Q Rev $6.47M >TNGX

Tango Therapeutics 1Q Rev $6.47M >TNGX

Dow JonesMay 8 19:03

Press Release: Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights -- Dose expansion initiated in TNG908 phase 1/2 clinical trial -- -- Dose expansion expected to initi

Dow JonesMay 8 19:01

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.

BusinesswireMay 8 19:00

Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know

Yahoo FinanceMay 7 22:00

Tango Therapeutics(TNGX.US) Insider Sells US$1.58 Million in Common Stock

$Tango Therapeutics(TNGX.US)$ Insider MVA Investors, LLC sold 210K shares of common stock on May 1, 2, 3, 2024 at an average price of $7.53 for a total value of $1.58 million. This transaction involve

Futu NewsMay 4 10:15

Form 144 | Tango Therapeutics(TNGX.US) Insider Proposes to Sell 455.4K in Common Stocks

SEC FILLINGS DISCLOSED/ May 3, $Tango Therapeutics(TNGX.US)$ Insider MVA Investors, LLC intends to sell 60,000 shares of its common stock on May 3, with a total market value of approximately $455.4K.

Futu NewsMay 4 09:37

Form 144 | Tango Therapeutics(TNGX.US) Insider Proposes to Sell 546K in Common Stocks

SEC FILLINGS DISCLOSED/ May 2, $Tango Therapeutics(TNGX.US)$ Insider MVA Investors, LLC intends to sell 75,000 shares of its common stock on May 2, with a total market value of approximately $546K.

Futu NewsMay 3 09:35

Form 144 | Tango Therapeutics(TNGX.US) Insider Proposes to Sell 577.5K in Common Stocks

SEC FILLINGS DISCLOSED/ May 1, $Tango Therapeutics(TNGX.US)$ Insider MVA Investors, LLC intends to sell 75,000 shares of its common stock on May 1, with a total market value of approximately $577.5K.

Futu NewsMay 2 09:38

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54

Zhitong FinanceMay 2 04:55

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Shareholders Might Be Looking For Exit

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) price-to-sales (or "P/S") ratio of 23x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where around hal

Simply Wall StApr 30 18:51

Cantor Fitzgerald Initiates Coverage On Tango Therapeutics With Overweight Rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Tango Therapeutics with a Overweight rating.

Analyst UpgradesApr 4 19:02